1. Home
  2. CHRS vs OPFI Comparison

CHRS vs OPFI Comparison

Compare CHRS & OPFI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CHRS
  • OPFI
  • Stock Information
  • Founded
  • CHRS 2010
  • OPFI 2009
  • Country
  • CHRS United States
  • OPFI United States
  • Employees
  • CHRS N/A
  • OPFI N/A
  • Industry
  • CHRS Biotechnology: Biological Products (No Diagnostic Substances)
  • OPFI Finance: Consumer Services
  • Sector
  • CHRS Health Care
  • OPFI Finance
  • Exchange
  • CHRS Nasdaq
  • OPFI Nasdaq
  • Market Cap
  • CHRS 84.2M
  • OPFI 336.3M
  • IPO Year
  • CHRS 2014
  • OPFI N/A
  • Fundamental
  • Price
  • CHRS $0.73
  • OPFI $14.05
  • Analyst Decision
  • CHRS Buy
  • OPFI Buy
  • Analyst Count
  • CHRS 3
  • OPFI 2
  • Target Price
  • CHRS $4.68
  • OPFI $11.75
  • AVG Volume (30 Days)
  • CHRS 1.3M
  • OPFI 1.4M
  • Earning Date
  • CHRS 08-07-2025
  • OPFI 08-06-2025
  • Dividend Yield
  • CHRS N/A
  • OPFI 7.15%
  • EPS Growth
  • CHRS N/A
  • OPFI N/A
  • EPS
  • CHRS N/A
  • OPFI N/A
  • Revenue
  • CHRS $272,251,000.00
  • OPFI $305,566,000.00
  • Revenue This Year
  • CHRS N/A
  • OPFI $112.80
  • Revenue Next Year
  • CHRS $106.56
  • OPFI $9.34
  • P/E Ratio
  • CHRS N/A
  • OPFI N/A
  • Revenue Growth
  • CHRS 19.87
  • OPFI 31.46
  • 52 Week Low
  • CHRS $0.66
  • OPFI $3.09
  • 52 Week High
  • CHRS $2.43
  • OPFI $17.73
  • Technical
  • Relative Strength Index (RSI)
  • CHRS 41.45
  • OPFI 63.93
  • Support Level
  • CHRS $0.72
  • OPFI $12.38
  • Resistance Level
  • CHRS $0.77
  • OPFI $14.81
  • Average True Range (ATR)
  • CHRS 0.04
  • OPFI 0.68
  • MACD
  • CHRS 0.00
  • OPFI 0.07
  • Stochastic Oscillator
  • CHRS 13.65
  • OPFI 84.99

About CHRS Coherus BioSciences Inc.

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.

About OPFI OppFi Inc.

OppFi Inc is a tech-enabled, mission-driven specialty finance platform that broadens the reach of community banks to extend credit access to everyday Americans. It recognizes revenue through finance charges on installment and SalaryTap contracts based on the interest method.

Share on Social Networks: